Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (578)	12/18/1997 11:44:00 PM
From: Miljenko Zuanic	Respond to of 887

>>Do you think there is any chance that DEPO will be able to make a case for improved efficiency or some way of counteracting the chemical arachnoiditis?<< My guess is that DepoFoam metabolite cause arachnoiditis because cytarabine is fairly quickly metabolized and drug didn't show this side effects. IF they are not severe and manageable should not be big problem, IF in concurrent studies DepoCyt show BETTER efficiency. >>How do you think the ODAC committee was able to spot chemical arachnoiditis and DEPO missed it?<< Depo didn't missed it. Probably they didn't think of it as a serious problem. I am still puzzled with 7 patients which didn't completed study? Reason(s)??? I was fortunate, pure luck, to cat my DEPO holding (small at beginning) after troubled market. Will hold, for now, until we have better picture on PIV and second PIII. mz